Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia

Blood

Volumn 92, Issue 9, 1998, Pages 3294-3301

  Minnema, M C ^a   Pajkrt, D ^b   Wuillemin, W A ^b   Roem, D ^b   Bleeker, W K ^b   Levi, M ^b   Van Deventer, S J H ^b   Hack, C E ^b   Ten Cate, H ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; ENDOTOXIN;

ADULT; ARTICLE; BLOOD CLOTTING; COMPLEX FORMATION; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0032212326     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.9.3294     Document Type: Article

References (45)

1. Naito K, Fujikawa K: Activation of human blood coagulation factor XI independent of factor XII. J Biol Chem 266:7353, 1991
2. Gailani D, Broze GJ: Factor XI activation in a revised model of blood coagulation. Science 253:909, 1991
3. von dem Borne PAK, Meijers JCM Bouma BN: Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86:3035, 1995
4. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477, 1995
5. von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN: Thrombin-mediated activation of factor XI results in a TAFI (thrombin-activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis. J Clin Invest 99:2323, 1997
6. Minnema MC, Friederich PW, Levi M, von dem Borne PAK, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H: Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 101:10, 1998
7. Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M: Thromboembolism and bleeding tendency in congenital factor XII deficiency-A study on 74 subjects from 14 Swiss families. Thromb Haemost 65:117, 1991
8. Seligsohn U: Factor XI deficiency. Thromb Haemost 70:68, 1993
9. von dem Borne PAK, Koppelman SJ, Bouma BN, Meijers JCM: Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 72:397, 1994
10. Wuillemin WA, Mertens K, ten Cate H, Hack CE: Thrombin-mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin. Br J Haematol 92:466, 1996
11. Scott CF, Colman RW: Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci USA 89:11189, 1992
12. Brunnée T, La Porta C. Reddighari SR, Salerno VM, Kaplan AP, Silverberg M: Activation of factor XI in plasma is dependent on factor XII. Blood 81:580, 1993
13. Levi M, ten Cate H, van der Poll T, van Deventer SJH: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 270:975, 1993
14. Taylor FB, Chang A, Ruf G, Morissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS: Lethal E. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127, 1991
15. Levi M, ten Cate H. Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJH, Hack CE. ten Cate JW, Rosenberg RD: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 94:114, 1994
16. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, Bogowitz CA, van der Poll T, Buller HR, ten Cate JW: Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 73:223, 1995
17. Pixley RA, de la Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB, Colman RW: The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 91:61, 1993
18. Pixley RA, de la Cadena R, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB: Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Path 140:897, 1992
19. de la Cadena R, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW: Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 81:3313, 1993
20. Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE: Quantification of plasma factor XIIa-Cl-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 72:1841, 1988
21. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW: α2-Macroglobulin-kallikrein complexes detect contact sytem activation in heriditary angioedema and human sepsis. Blood 77:2660, 1991
22. Wuillemin WA, Minnema MC, Meijers JCM, Roem D, Eerenberg AIM, Nuijens JH, ten Gate H, Hack CE: Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood 85:1517, 1995
23. Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Meijers JCM, Bouma BN, Hack CE: Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman Factor). J Biol Chem 264:12941, 1989
24. Ravon DM, Citarella F, Lubbers TY, Pascucci B, Hack CE: Monoclonal antibody Fl binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 86:4134, 1995
25. Wuillemin WA, Fijnvandraat K, Derkx BHF, Peters M, Vreede W, ten Cate H, Hack CE: Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 74:1436, 1995
26. Gruber A, Griffin JH: Direct detection of activated protein C in blood from human subjects. Blood 79:2340, 1992
27. Sala N, Owen WG, Collen D: A functional assay of protein C in human plasma. Blood 63:671, 1984
28. Tans G, Janssen-Claessen T, Rosing J, Griffin JH: Studies on the effect of serine protease inhibitors on activated contact factors. Eur J Biochem 164:637, 1987
29. Nuijens JH, Huijbregts CCM, Cohen M, Navis GO, de Vries A, Eerenberg AJM, Bakker JC, Hack CE: Detection of activation of the contact system of coagulation in vitro and in vivo: Quantification of activated Hageman factor-C 1 -inhibitor and kallikrein-C1 -inhibitor complexes by specific radioimmunoassays. Thromb Haemost 58:778, 1987
30. Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, Thijs LG, Hack CE: Proteolytic inactivation of plasma Cl inhibitor in sepsis. J Clin Invest 84:443, 1989
31. Pieters J, Lindhout T, Willems G: Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma. Blood 76:549, 1990
32. Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten Cate H: Inactivation of factor XIa in vivo: Studies in chimpanzees and in humans. Thromb Haemost 76:549, 1996
33. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30:10363, 1991
34. Lawson JH, Kalafatis M, Stram S, Mann KG: A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269:23357, 1994
35. Sinha D, Seaman FS, Koshy A, Knight LC, Walsh PN: Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. J Clin Invest 73:1550, 1984
36. Berrettini M, Schleef RR, Heeb MJ, Hopmeier P, Griffin JH: Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells. J Biol Chem 267:19833, 1992
37. Schmaier AH, Murray SC, Heda GD, Fraber A, Kuo A, McCrae K, Cines DB: Synthesis and expression of Cl inhibitor by human umbilical vein endothelial cells. J Biol Chem 264:18173, 1989
38. Mertens G, Cassiman JJ, van den Berghe H, Vermylen J, David G: Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. J Biol Chem 267:20435, 1992
39. van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD: Protease nexin II (amyloid β-protein precursor): A platelet α-granule protein. Science 248:745, 1990
40. Smith RP, Higuchi DA, Broze GJ: Platelet coagulation factor XIa-inhibitor, a form of alzheimer amyloid precursor protein. Science 248:1126, 1990
41. Lewin MF, Kaplan AP, Harpel PC: Studies of Cl inactivator-plasma kallikrein complexes in purified systems and in plasma. J Biol Chem 258:6415, 1983
42. Kaplan AP, Gruber B, Harpel PC: Assessment of Hageman factor activation in human plasma: Quantification of activated Hageman factor-Cl inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood 66:636, 1985
43. van Deventer SJH, Buller HR, ten Gate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement path-ways. Blood 78:2520, 1990
44. Pixley RA, Zellis S, Bamkes P, de la Cadena R, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW: Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 23:41, 1995
45. Gonias SL, Pizzo SV: Chemical and structural modifications of α2-macroglobulin: Effects on receptor binding and endocytosis studied in a in vivo model. Ann NY Scad Sci 421:457, 1983